Clin Res Cardiol (2018) 107:201–213 DOI 10.1007/s00392-017-1172-4 ORIGINAL PAPER Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease 1 1 2 1 Insa E. Emrich · Adam M. Zawada · Jens Martens-Lobenhoffer · Danilo Fliser · 3 1 2 Stefan Wagenpfeil · Gunnar H. Heine · Stefanie M. Bode-Böger Received: 24 August 2017 / Accepted: 20 October 2017 / Published online: 3 November 2017 © Springer-Verlag GmbH Germany 2017 Abstract annually for CKD progression and for incident atheroscle- Background Chronic kidney disease (CKD) is associated rotic cardiovascular events. with increased risk of renal and cardiovascular events. It has Results During 5.1 ± 2.1 years follow-up, 80 patients dis- been claimed that endogenous methylarginines, asymmetric played CKD progression and 145 patients developed inci- dimethylarginine (ADMA) and symmetric dimethylarginine dent atherosclerotic cardiovascular events. In univariate (SDMA), are contributing factors. However, earlier studies Cox regression analyses, elevated plasma levels of all five were partly contradictory and mainly focused on prevalent metabolites were associated with both CKD progression and dialysis patients. Moreover, the potential contribution of atherosclerotic cardiovascular disease. However, adjustment degradation products, such as acetylated ADMA and SDMA for confounders attenuated the prognostic implications of (AcADMA and AcSDMA) and other methylarginines ADMA, LNMMA, AcADMA and
Zeitschrift für Kardiologie – Springer Journals
Published: Nov 3, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud